Resolute Integrity US A Postapproval Study of the Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm [SUBSTUDY OF 700220310]

Trial Profile

Resolute Integrity US A Postapproval Study of the Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm [SUBSTUDY OF 700220310]

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms RI-US XL
  • Sponsors Medtronic
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 1 Dec 2020 to 1 Oct 2020.
    • 09 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Oct 2015 Planned End Date changed from 1 Jan 2022 to 1 Dec 2020 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top